Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 47335-894

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 47335-894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Spl-clopidogrel-chemical-structure (Spl Clopidogrel Chemical Structure)

Chemical structure of clopidogrel bisulfate showing its molecular arrangement including a thiophene ring, a chlorophenyl group, and a carboxylate methyl ester, accompanied by a sulfate molecule (H2SO4).*

FDA Label Image

Spl-clopidogrel-fig-7 (Spl Clopidogrel Fig 7)

A line graph titled "Fatal or Nonfatal Vascular Events in the CAPRIE Study" comparing cumulative event rates (%) over 36 months of follow-up between patients taking Aspirin and Clopidogrel. The graph shows event rates increasing over time, with Aspirin having a slightly higher cumulative event rate than Clopidogrel. A statistical value of P=0.045 is indicated.*

FDA Label Image

Spl-clopidogrel-fig-8 (Spl Clopidogrel Fig 8)

A forest plot chart titled 'Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study,' comparing Clopidogrel versus Aspirin across qualifying conditions Stroke, MI, and PAD, showing hazard ratios with 95% confidence intervals and an overall result. The horizontal axis ranges from 0.6 to 1.3, indicating relative favor towards Clopidogrel or Aspirin.*

FDA Label Image

Spl-clopidogrel-figure1 (Spl Clopidogrel Figure1)

A graph showing the effect of coadministered proton pump inhibitors (PPIs) on exposure to clopidogrel active metabolite after multiple 75 mg doses. The chart presents the mean and 90% confidence interval of active metabolite AUC changes relative to clopidogrel alone for Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg.*

FDA Label Image

Spl-clopidogrel-figure2 (Spl Clopidogrel Figure2)

A line graph titled 'Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study' showing cumulative event rates (%) on the y-axis over 12 months of follow-up on the x-axis. It compares placebo plus aspirin and clopidogrel plus aspirin, with lower event rates observed in the clopidogrel group throughout the study period.*

FDA Label Image

Spl-clopidogrel-figure3 (Spl Clopidogrel Figure3)

A forest plot displaying hazard ratios with 95% confidence intervals for various patient baseline characteristics and on-study concomitant medications or interventions in the CURE Study. The plot compares Clopidogrel and placebo groups across subgroups such as age, gender, race, enzyme elevation, diabetes, previous myocardial infarction and stroke, use of heparin/LMWH, aspirin dosage, GP IIb/IIIa antagonist, beta-blocker, and ACE inhibitor, as well as overall effect. Each subgroup shows numeric data for Clopidogrel and placebo patients and corresponding hazard ratios with confidence intervals.*

FDA Label Image

Spl-clopidogrel-figure4 (Spl Clopidogrel Figure4)

A line graph titled 'Cumulative Event Rates for Death in the COMMIT Study' showing the percentage of deaths before first discharge over 28 days since randomization. The y-axis represents % dead before discharge, and the x-axis shows days up to 28. Two lines compare placebo (8.1% deaths) and clopidogrel (7.5% deaths), noting a 7% proportional risk reduction (p=0.03). A footnote states all treated patients received aspirin.*

FDA Label Image

Spl-clopidogrel-figure5 (Spl Clopidogrel Figure5)

A cumulative event rates graph from the COMMIT Study showing the combined endpoint of reinfarction, stroke, or death for Clopidogrel versus placebo over 28 days post-randomization. The y-axis shows percentage with death, reinfarction, or stroke before discharge, and the x-axis shows days since randomization. The graph indicates a 9% proportional risk reduction in the Clopidogrel group compared to placebo.*

FDA Label Image

Spl-clopidogrel-figure6 (Spl Clopidogrel Figure6)

A forest plot chart showing the effects of adding Clopidogrel to aspirin on a combined primary endpoint across various baseline and concomitant medication subgroups in the COMMIT study. The chart lists subgroups by gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, showing odds ratios with confidence intervals comparing Clopidogrel and placebo groups.*

FDA Label Image

Spl-clopidogrel-label (Spl Clopidogrel Label)

Label for Clopidogrel Tablets USP 75 mg film-coated tablets, oral use. The label states each tablet contains 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base. It shows a package size of 90 tablets and is labeled for prescription use only. Manufactured and distributed by Sun Pharmaceutical Industries, Inc., with addresses in India and New Jersey, USA. Includes storage instructions and legal patent information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.